LOXL2 and Hepatic fibrosis: While the anti-LOXL2 mAb had a modest impact on collagen deposition, PAT-1251 robustly and dose-dependently reduced liver fibrosis as assessed by both histological analysis of collagen deposition (Figures 2A, B) and biochemical analysis of hepatic hydroxyproline content.